Anorexia News and Research

RSS

EMEND indication helps women prevent CINV

More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy. Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting, CINV remains a significant problem in the context of current practice.

26 May 2010

Psychologists and neuroscientists study link between brain volume reduction and anorexia

A team of American psychologists and neuroscientists have found that adult brain volume, which can be reduced by Anorexia Nervosa, can be regained. The research, published in the International Journal of Eating Disorders, revealed that through specialist treatment patients with the eating disorder can reverse this symptom and regain grey matter volume.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

Malnutrition presents a serious social problem in Bulgaria

According to a strategic document published by the World Bank (2006), malnutrition leads to indirect losses in productivity from poor cognitive development and schooling.

24 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

EDNOS categorization for young people needs to be reconsidered

Diagnostic cutoffs for anorexia nervosa and bulimia nervosa may be too strict, a study from the Stanford University School of Medicine and Lucile Packard Children's Hospital has found. Many patients who do not meet full criteria for these diseases are nevertheless quite ill, and the diagnosis they now receive, "Eating Disorder Not Otherwise Specified," may delay their ability to get treatment.

12 Apr 2010

Binge eating: Helping to stop binging while saving money

A new study finds that a self-guided, 12-week program helps binge eaters stop binging for up to a year and the program can also save money for those who participate. Recurrent binge eating is the most common eating disorder in the country, affecting more than three percent of the population, or nine million people, yet few treatment options are available.

1 Apr 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Feelings of guilt and shame haunt mothers with eating difficulties

They would love to be perfect mothers. Instead, they feel ashamed and inadequate, and fearful that their children might inherit their eating difficulties.

18 Mar 2010

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Study explores incidence of eating disorders among type 1 diabetic patients

Diabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.

12 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

Aesthetic sports sanction behaviors more consistent with eating disorders than healthy living

The control and perfectionism that set Olympic athletes apart from their peers at lower levels of competition often have a darker side, according to Kimberly Dennis, M.D., a leading psychiatrist specializing in eating disorder treatment.

22 Feb 2010

Lucile Packard Children’s Hospital gearing up for National Eating Disorders Awareness Week

Lucile Packard Children’s Hospital at Stanford is gearing up for National Eating Disorders Awareness Week, Feb. 21 – 27. The hospital's Comprehensive Eating Disorders Program is reaching out to Bay Area families to enhance knowledge of anorexia nervosa, bulimia nervosa and related diagnoses.

19 Feb 2010

Anorexia News and Research

EMEND indication helps women prevent CINV

Psychologists and neuroscientists study link between brain volume reduction and anorexia

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Malnutrition presents a serious social problem in Bulgaria

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Targeted therapy MDV3100 is effective for patients with CRPC: Study

EDNOS categorization for young people needs to be reconsidered

Binge eating: Helping to stop binging while saving money

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Feelings of guilt and shame haunt mothers with eating difficulties

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Study explores incidence of eating disorders among type 1 diabetic patients

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Aesthetic sports sanction behaviors more consistent with eating disorders than healthy living

Lucile Packard Children’s Hospital gearing up for National Eating Disorders Awareness Week

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News